Assessment of tumor response to immune checkpoint inhibitors using chest magnetic resonance imaging
Not Applicable
- Conditions
- advanced lung cancer
- Registration Number
- JPRN-UMIN000023462
- Lead Sponsor
- Hamamatsu University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Autoimmune disease. Interstitial lung disease. Severe comorbidities. Uncontrolled central nerve system lesion. Severe renal disorder. Inapplicable for MRI.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of tumor response 4 weeks after immune checkpoint therapy.
- Secondary Outcome Measures
Name Time Method Evaluation of tumor response 2 and 8 weeks after immune checkpoint therapy.